secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMPACT BIOMEDICAL INC. (IBO)
CIK:        0001834105
Form:       8-K
Filed at:   2026-03-04T23:59:59+00:00
Accession:  0001493152-26-008879
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Impact BioMedical amends merger deal with Dr Ashleys; extends deadline to July 1, 2026
--------------------------------------------------------------------------------

- Amendment adds 53,000 and 75,000 PubCo ordinary shares to be issued to DSS, Inc. at closing.
- Total Company Share Consideration set at 169,560,000 PubCo shares (94.20% of post-closing outstanding).
- Termination date extended from March 31, 2026 to July 1, 2026, with mutual extension option.
- Impact must seek board approval to co-sign loan agreements requested by PubCo or Dr Ashleys before effective time.
- Supporting stockholders now hold 92,980,843 Impact shares (88.87% fully diluted); holdings of DSS, Inc. and DSS BioHealth updated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1834105/000149315226008879/0001493152-26-008879-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1834105/000149315226008879/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-008879

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer